Literature DB >> 3394811

Effect of adenosine analogues on tubuloglomerular feedback responses.

J Schnermann1.   

Abstract

Adenosine has been invoked as a possible mediator of the vasoconstrictor response elicited through the tubuloglomerular feedback mechanism. These experiments were undertaken to study the effect of adenosine analogues on the magnitude of the stop-flow pressure (SFP) feedback response. With a control solution, maximum change of SFP during orthograde perfusion was 6.3 +/- 0.34 mmHg. When the adenosine1 (A1) receptor agonists CHA, CPA, or R-PIA were present in the perfusate in a concentration of 10(-5) M, SFP responses were significantly augmented and averaged 12.6 +/- 1.9 (P less than 0.001), 12.6 +/- 0.8 (P less than 0.001), and 10.3 +/- 1.1 mmHg (P less than 0.02), respectively. Diminished responses were seen at higher concentrations of A1 analogues. The A2-receptor agonist NECA did not significantly modify the control response at 10(-5) M, but reduced its magnitude at higher concentrations. During graded increases in loop flow rate essentially all of the response in the presence of CPA or R-PIA occurred in the 0-10 nl/min flow interval, whereas the most sensitive flow rate range in the control tubules was between 10 and 20 nl/min. In the presence of 10(-4) M furosemide SFP responses were abolished during perfusion with the control and NECA-containing solutions. In contrast, SFP fell by 11.8 +/- 1.26 mmHg and 8.7 +/- 1.25 mmHg with CHA or CPA solutions despite the presence of furosemide. Perfusion with 10(-6) M CPA in an isotonic mannitol solution was associated with a decrease of SFP by 16.3 +/- 1.42 mmHg, whereas the mannitol solution alone decreased SFP by only 0.6 +/- 0.18 mmHg. Our results show that luminal administration of A1-receptor analogues increases SFP feedback response magnitude, an effect that does not require the presence of a luminal NaCl signal.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3394811     DOI: 10.1152/ajprenal.1988.255.1.F33

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

1.  Immunolocalization of ecto-5'-nucleotidase in the kidney by a monoclonal antibody.

Authors:  R Gandhi; M Le Hir; B Kaissling
Journal:  Histochemistry       Date:  1990

2.  Adenosine A(2) receptors modulate tubuloglomerular feedback.

Authors:  Mattias Carlström; Christopher S Wilcox; William J Welch
Journal:  Am J Physiol Renal Physiol       Date:  2010-06-02

3.  ATP, P2 receptors and the renal microcirculation.

Authors:  Edward W Inscho
Journal:  Purinergic Signal       Date:  2009-03-18       Impact factor: 3.765

4.  Adenosine A2A receptor activation attenuates tubuloglomerular feedback responses by stimulation of endothelial nitric oxide synthase.

Authors:  Mattias Carlström; Christopher S Wilcox; William J Welch
Journal:  Am J Physiol Renal Physiol       Date:  2010-11-24

5.  Effect of adenosine1-receptor blockade on renin release from rabbit isolated perfused juxtaglomerular apparatus.

Authors:  H Weihprecht; J N Lorenz; J Schnermann; O Skøtt; J P Briggs
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

6.  Distribution of 5'-nucleotidase in the renal interstitium of the rat.

Authors:  M Le Hir; B Kaissling
Journal:  Cell Tissue Res       Date:  1989-10       Impact factor: 5.249

7.  Physiological role for P2X1 receptors in renal microvascular autoregulatory behavior.

Authors:  Edward W Inscho; Anthony K Cook; John D Imig; Catherine Vial; Richard J Evans
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

Review 8.  Renal blood flow control by tubuloglomerular feedback (TGF) in normal and spontaneously hypertensive rats--a role for dopamine and adenosine.

Authors:  D A Häberle; B Königbauer; M Kawabata; Y Ushiogi
Journal:  Klin Wochenschr       Date:  1991-09-03

Review 9.  Adenosine and kidney function: potential implications in patients with heart failure.

Authors:  Volker Vallon; Cindy Miracle; Scott Thomson
Journal:  Eur J Heart Fail       Date:  2008-02-01       Impact factor: 15.534

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.